Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BT002
- Development stage
- Preclinical
- Lead developer
- Bone-Tech
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
**BT002**, also called **OsteoActivator-M**, is a preclinical, locally administered extended-release combination product being developed for bone repair and osteoarthritis-associated subchondral bone remodeling. It uses injectable biodegradable poly(lactic-co-glycolic acid) microspheres to provide sustained local delivery of testosterone, intended to enhance osteoblast-mediated bone formation, together with alendronate, intended to inhibit osteoclast-mediated bone resorption. The product is intended for osteoarthritis, bone defects and trauma-related injuries, including vertebral compression fractures. ([osteo-pharma.com](https://www.osteo-pharma.com/product-pipeline/))
- Other names
- OsteoActivator-M
02
Targets
AR (Adrenergic receptors)FDPS (Farnesyl pyrophosphate synthase)
Beyond the preview
Go deeper on BT002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BT002.